<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04926142</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A03417-32</org_study_id>
    <nct_id>NCT04926142</nct_id>
  </id_info>
  <brief_title>Prevalence of Atrial Fibrillation in Cryptogenic Stroke With Patent Foramen Ovale Closure (PFO-AF) Study</brief_title>
  <acronym>PFO-AF</acronym>
  <official_title>Prevalence of Atrial Fibrillation in Cryptogenic Stroke With Patent Foramen Ovale Closure (PFO-AF) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the incidence of atrial fibrillation (AF), documented using data&#xD;
      recorded by an implantable Holter monitoring device (Reveal Linq, Medtronic) within 2 years&#xD;
      after percutaneous closure of patent foramen ovale for cryptogenic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to assess the incidence of atrial fibrillation (AF), documented using data&#xD;
      recorded by an implantable Holter monitoring device (Reveal Linq, Medtronic) within 2 years&#xD;
      after percutaneous closure of patent foramen ovale (PFO) for cryptogenic stroke. Secondary&#xD;
      objectives include assessment of the burden of AF at 2, 12 and 24 months after PFO closure;&#xD;
      evaluation of the relationship between plasma levels of MR proANP and presence of AF within 2&#xD;
      years after percutaneous PFO closure in patients with a history of cryptogenic ischemic&#xD;
      stroke; and description of recurrence rates for stroke (ischemic and hemorrhagic), major&#xD;
      bleeding, minor bleeding, peripheral emboli during the 2-year follow-up period after&#xD;
      percutaneous PFO closure, in patients with and without AF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>Within 24 months after percutaneous PFO closure</time_frame>
    <description>Occurrence of documented atrial fibrillation (i.e. at least one episode lasting 30 seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Burden of atrial fibrillation</measure>
    <time_frame>Within 2 years after percutaneous PFO closure</time_frame>
    <description>Cumulative total time in atrial fibrillation (in days, hours, minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relation between MR proANP levels and atrial fibrillation</measure>
    <time_frame>Within 2 years after percutaneous PFO closure</time_frame>
    <description>Relation between pre-procedure circulating venous MR proANP levels and atrial fibrillation defined as per the primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Within 2 years after percutaneous PFO closure</time_frame>
    <description>Ischemic or hemorrhagic stroke documented by CT or MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral emboli</measure>
    <time_frame>Within 2 years after percutaneous PFO closure</time_frame>
    <description>Peripheral emboli by CT or MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>Within 2 years after percutaneous PFO closure</time_frame>
    <description>Major or minor bleeding according to the ISTH classification</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Patent Foramen Ovale</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Patients planned for percutaneous PFO closure</arm_group_label>
    <description>Patients will undergo implantation of a Holter device (Reveal Linq Medtronic) 2 months prior to percutaneous PFO closure. Devices will be monitored by telemonitoring until the PFO closure procedure, and at 2, 12 and 24 months after the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of Holter device</intervention_name>
    <description>Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm</description>
    <arm_group_label>Patients planned for percutaneous PFO closure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous PFO closure</intervention_name>
    <description>Patients will undergo percutaneous closure of patent foramen ovale</description>
    <arm_group_label>Patients planned for percutaneous PFO closure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective patients who have had cryptogenic stroke (ischemic only) and with patent&#xD;
        foramen ovale confirmed by transoesophageal echocardiography, with an indication for&#xD;
        percutaneous closure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (aged &gt;18 years)&#xD;
&#xD;
          -  with an indication for percutaneous closure of PFO due to cryptogenic stroke, with&#xD;
             indication validated by a cardio-neurological team.&#xD;
&#xD;
          -  patients must provide written informed consent&#xD;
&#xD;
          -  patients must be affiliated to a social security regime or be a beneficiary thereof.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under legal protection&#xD;
&#xD;
          -  Patients not affiliated to any social security regime&#xD;
&#xD;
          -  Patients within the exclusion period of another clinical trial as per the national&#xD;
             registry of research volunteers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Badoz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Badoz, MD</last_name>
    <phone>33381668185</phone>
    <email>mbadoz@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Line Perruche</last_name>
    <phone>33381669434</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Besancon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Badoz, MD</last_name>
      <phone>33381668185</phone>
    </contact>
    <contact_backup>
      <last_name>ML Perruche</last_name>
      <phone>33381669434</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Lyon - Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles Rioufol, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc Lorgis, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Defaye, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

